On March 16, 2023, YS Biopharma Co., Ltd. (YS Biopharma) completed the business combination with Summit Healthcare Acquisition Corp. (Summit Healthcare), a publicly traded special purpose acquisition company (the merger). From March 17, YS Biopharma will become a publicly listed company and its shares and warrants will begin trading on the Nasdaq Capital Market under the symbols “YS” and “YSBPW,” respectively.

YS Biopharma is a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologics for infectious diseases and cancer.

The Wilson Sonsini Goodrich & Rosati team representing YS Biopharma in the merger and Nasdaq listing includes:

Corporate
Dan Ouyang
Ke Li
Zhenzhen Bao
Haoqian Chen
Kelvin Lam

Tax
Myra A. Sutanto Shen

For more information, please see the press release.